| October 31, 2013 | ISSUE NUMBER 324 VOL 11 |
Regulatory
Transparency Trouble for Pharma
High prices, murky financial relations, and a reluctance to disclose clinical data are undermining public trust in industry and the research enterprise, writes Jill Wechsler ...Read more
Marketing & Social Media
Digital Marketing is Dead, Long Live Marketing
The days of digital marketing as we know it are over. Pharma companies need to step into a new world where branding is more seamlessly integrated across media, writes Peter Houston ...Read more
Global
Pharm Exec Global Digest — Real World Evidence Special
In this issue: learning to live and work with the Real World Evidence future — integrating RWE into your business strategy as painlessly as possible; Retrospective Studies — real world data, real world applications; Outcomes Data — getting ROI on your HEOR; and more! ...Read more
Earn an Online Master’s Degree from the University of Florida!
Advance your education and career by earning a Master of Science in Pharmaceutical Outcomes and Policy. Learn the skills necessary to compete in this new marketplace.
Our flexible program allows you to choose courses, offered online, from various specialties. Earn your master’s degree in two years or choose a graduate certificate in one of our specialty tracks. Visit our website to apply
Video
PhRMA: Leveling the Playing Field for Innovation
Robert Hugin, Chairman of Celgene and PhRMA, talks about the challenges ahead for the industry organization ...Watch here
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now.
Special Feature
The 12th Annual Pharm Exec Industry Audit
The Pharm Exec Industry Audit holds a unique position in the increasingly crowded field of data sets tracking industry performance. It adheres to a simple objective: to identify how well companies are doing in advancing shareholder value. For an overview of the metrics we used to assess company performance this year (and thus decide on our winner), click here ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now.
|
|
|
|
 //Jackson Tai, a senior banker with experience as Vice Chairman and CEO of Asian financial firm DBS, will join the Board of Lilly on November 1.//Michael Wyzga, CEO of Genzyme from 1998 to 2011, joined the Board of Directors of OncoMed (Redwood City, CA).//The Cardiovascular Research Foundation (New York, NY) named Jack Lewin as its new president and CEO.//Almac’s Clinical Services Business Unit announced that Richard Segiel, Jr. joined the company as Vice President of Business Development for the US.//Global contract development and manufacturing organization Aesica (Neptune, NJ) appointed Baali Muganga to the role of East Coast US Business Development Manager.// |
|
|
|
|
|
 |
|
|
|
| |
|
|
|
 |
|
 |
Which area of pharma has the global recession impacted the most?
|
|
|
|
